advertise

Wednesday 19 November 2014

China Recombinant Protein Drug Industry Report 2014-2017 - Global Market size, share, analysis and focus

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein drugs exceed RMB40 billion in 2014.

To Brows a Full Report with Toc: http://www.researchmoz.us/china-recombinant-protein-drug-industry-report-2014-2017-report.html

The start of recombinant protein drugs in China is not late and common drugs are diversified in variety, for example, recombinant human erythropoietin (rhEPO), recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interferon (rhIFN) have gained market approval in the 1990s. Moreover, in 2013, domestic rhG-CSF, rhEPO andrecombinant human growth hormone (rhGH) with price advantage took a respective share of 82.1%, 88.5% and 90.2% in Chinese sample hospitals, and recombinant human interleukin-2/11(rhIL-2/11) was fully localized.

However, as compared with products from leading bio-pharmaceutical enterprises in the United States and Europe, domestic recombinant protein drugs are still characterized by low-end technologies and largely remain in common short-acting areas. And foreign brands still prevail in the markets of recombinant insulin, rhIFN, recombinant coagulation factor and recombinant human follicle-stimulating hormone (rhFSH).

1. Recombinant Insulin Market. In 2013,foreign brands such asNovo Nordisk’s insulin aspart and insulin detemir, Sanofi’s insulin glargine, Eli Lilly’s insulin lispro accounted for 91.4% of recombinant insulin market of Chinese sample hospitals, while domestic insulin e.g. insulin glargine and insulin lispro of Gan & Lee Pharmaceuticals, recombinant insulin of Tonghua Dongbao Pharmaceuticaland animal insulin of Wanbang Biopharmaceuticalswas at a distinct disadvantage, whereas insulin analog products of Gan & Lee are still in the process of development, with huge potential for growth in the future.

2. rhIFN-αMarket.Roche's PEG-IFNα-2a, MSD’s PEG-IFNα-2a and IFN-α-2a, and other imported products still dominate Chinese interferon market, sweeping as much as 70.7% of recombinant interferon market of sample hospitals in 2013; whilemore than a dozen local companies like Shanghai Huaxin High Biotechnology Inc., Beijing Tri-Prime Genetic Engineering Co., Ltd. and Anhui Anke Biotechnology (Group) Co., Ltd.mainly produce ordinary short-acting products, which lack strong competitiveness compared with PEG-Intron products (long-acting interferon)with better anti-hepatitisvirus effect.

Moreover, there is no domestic recombinant protein drug in such markets as rhIFN-β, rhFSH, recombinant coagulation factor VIIa and factorVIIIyet.

Based on support from favorable policies, R&D ability enhancement as well as being optimistic about market prospects, a large number of biotech companies are vigorously developing long-acting, high-end protein drugs.

In August 2014, PEG-rhGHof GeneScience Pharmaceuticals Co., Ltd. (GenSci, a subsidy of Changchun High & New Technology Industry (Group) Inc.) obtained the GMP certificate and could formally go on sale; however, as PEG-rhGHbelongs to national new First-in-Class drugs, a phase IV clinical trial is a must, and mass production is expected to begin in 2016. In June 2014, Anke Biotechnology’s PEG-rhIFNαand Dongbao Pharmaceutical’sultrolente insulin (insulin glargine)were both approved for clinical application. So far,PEG-GCSF of Jiangsu Hengrui Medicine Co., Ltd., PEG-rhIFNαof Xiamen Amoytop Biotech Co., Ltd. (a subsidiary of Dongbao Pharmaceutical) and rhFSH of GenSci have all declared for production and are expected to be approved and availableon the market in 2015.

Table of Content

1. Overview of Recombinant Protein Drug Industry
1.1 Definition
1.2 Classification

2. Development of Recombinant Protein Drugs in China
2.1 Market Worldwide
2.2 Market Segments Worldwide
2.2.1 Insulin
2.2.2 Recombinant Human Interferon (rhIFN)
2.2.3Recombinant Human Erythropoietin (rhEPO)
2.2.4 Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
2.2.5Recombinant Human Growth Hormone (rhGH)
2.2.6 Recombinant Human Follicle-stimulating Hormone (rhFSH)
2.3 Market in China
2.3.1 Market Size
2.3.2 Competition Pattern
2.4 Prospects
2.4.1 Market Worldwide
2.4.2 Market in China

3. Recombinant Protein Drug Market Segments in China

All Repoers of this Category Here: http://www.researchmoz.us/biotechnology-market-reports-30.html

About ResearchMoz


ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact US: 


For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/

No comments:

Post a Comment